Entospletinib

DB12121InvestigationalSmall molecule

Entospletinib has been used in trials studying the treatment of Oncology, Follicular Lymphoma, B-cell Malignancies, Mantle Cell Lymphoma, and Non-Hodgkin Lymphoma, among others.

Mechanism: Pharmacologically active on Tyrosine-protein kinase SYK
Curator reviewed
Formula / weight: C₂₃H₂₁N₇O · 411.4591 g/mol (avg)
Code names: GS-9973

Resolves to

Compound

UNII6I3O3W6O3BCAS1229208-44-9ChEMBLCHEMBL3265032PubChem59473233

Structure

InChIKeyXSMSNFMDVXXHGJ-UHFFFAOYSA-NSMILESC1CN(CCO1)C1=CC=C(NC2=NC(=CN3C=CN=C23)C2=CC3=C(C=NN3)C=C2)C=C1

Targets

P43405SYK

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

14Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Entospletinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account